ASCO 2021 | Preliminary safety and efficacy of PBCAR0191 in R/R CD19+ NHL
Bijal Shah, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses preliminary safety and efficacy findings from a Phase I trial (NCT03666000) of PBCAR0191 in relapsed/refractory CD19+ non-Hodgkin lymphoma (NHL). Dr Shah gives an overview of the trial, highlighting novel approaches to chimeric antigen receptor (CAR) T-cell manufacturing. Dr Shah discusses data from patients who underwent intensified lymphodepletion with increased doses of cytarabine and cyclophosphamide before receiving PBCAR0191. This cohort reported a complete response rate of 71% at 28 days of follow-up. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Bijal Shah, MD, has received research funding from Kite/Gilead and Jazz Pharmaceuticals; has participated in an advisory role with Kite/Gilead, BMS/Celgene, Novartis, Precision Biomedicines, Adaptive, Jazz Pharma, Servier, AstraZeneca and Beigene.
